Proscillaridin
Systematic (IUPAC) name | |
---|---|
5-[(3S,8R,9S,10R,13R,14S,17R)- 14-hydroxy- 10,13-dimethyl- 3-((2R,3R,4R,5R,6R)- 3,4,5-trihydroxy- 6-methyltetrahydro- 2H-pyran-2-yloxy)- 2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro- 1H-cyclopenta[a]phenanthren- 17-yl]- 2H-pyran- 2-one OR 3β-Rhamnosido- 14β-hydroxybufa- 4,20,22-trienolide | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 466-06-8 |
ATC code | C01AB01 (WHO) |
PubChem | CID 5284613 |
ChemSpider | 4447658 |
UNII | KC6BL281EN |
ChEMBL | CHEMBL600325 |
Chemical data | |
Formula | C30H42O8 |
Molar mass | 530.650 |
| |
| |
(what is this?) (verify) |
Proscillaridin is a cardiac glycoside, a kind of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). It is of the bufanolide type and can be obtained from plants of the genus Scilla and in Drimia maritima (Scilla maritima).[1]
References
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.